Fig. 4
From: Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery
AMPG enhances the anticancer effects of ECH in HepG2 cells. Cell viability of (A) HepG2 and (B) LO2 cells incubated with different concentrations of ECH for 0, 12, 24, and 48 h. C CLSM images (blue: nuclei stained with DAPI; red: Cy7-labeled AM; green: cytoskeleton stained with FITC–phalloidin). Scale bars, 100 μm. D TEM images showing intracellular distribution of AMPG in HepG2 cells. Scale bars, 2 μm. E Cell apoptosis, F OCR, G ECAR, and I UBR5, LDHA, PKM2, Survivin, C-myc, and β-catenin expression in HepG2 cells incubated with ECH, AMPG, and ECH@AMPG. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control. ###P < 0.001 compared to ECH